Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial

Ghaderkhani, Sara; Khaneshan, Arezoo Salami; Salami, Amir; Alavijeh, Parvaneh Ebrahimi; Kouchak, Hamid Emadi; Khalili, Hossein; Naghi, Seyed Ahmad Ali; Ahmadinejad, Zahra; Rasolinejad, Mehrnaz; Hajiabdolbaghi, Mahboubeh; Jafari, Sirous; Hasannezhad, Malihe; Seifi, Arash; Abasian, Ladan; Ghiasvand, Fereshte; Avanaki, Foroogh Alborzi; Edalatifard, Maryam; Rahimi, Mojgan

doi:10.21203/rs.3.rs-91430/v1

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В отношении коронавируса SARS-CoV-2 механизм действия УМФ связан с блокированием этапа фузии на уровне взаимодействия поверхностного S-белка коронавирусов и рецептора АСЕ2 на поверхности клеток человека [16]. Результаты контролируемых рандомизированных исследований, проведенных в Иране, показали, что УМФ сокращает сроки десатурации и выздоровления пациентов, снижает частоту госпитализации в отделения интенсивной терапии [17,20]. Ретроспективные исследования также показывают, что прием УМФ снижал смертность госпитализированных пациентов [21] Применение препаратов ИФН в монотерапии или в комплексной ПВТ показало положительный эффект (уменьшение катаральных явлений и синдрома интоксикации), вероятно, связанный с недостаточным интерфероновым ответом на ранних этапах заболевания [23,24].…”

Section: Discussionunclassified

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Pshenichnaya

Карева

Leneva

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.

show abstract

Section: Discussionunclassified

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Pshenichnaya

Карева

Leneva

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…Furthermore, Li et al [106] concluded that ARB was superior to HCQ in terms of duration of hospital stay and SARS-CoV-2 negative conversion. Moreover, a randomized control trial proved the higher benefit in using ARB over HCQ, as it was responsible for the improvement of clinical symptoms and recovery rate [105].…”

Section: Arbidol (Arb)mentioning

confidence: 97%

Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far

et al. 2021

View full text Add to dashboard Cite

Human beings around the globe have been suffering from a devastating novel pandemic and public health emergency, coronavirus disease 2019 (COVID-19), for more than one and a half years due to the deadly and highly pathogenic severe acute respiratory coronavirus 2 (SARS-CoV-2) infection worldwide. Notably, no effective treatment strategy has been approved for the complete recovery of COVID-19 patients, though several vaccines have been rolled out around the world upon emergency use authorization. After the emergence of the COVID-19 outbreak globally, plenty of clinical investigations commenced to screen the safety and efficacy of several previously approved drugs to be repurposed against the SARS-CoV-2 pathogen. This concise review aims at exploring the current status of the clinical efficacy and safety profile of several antiviral medications for the treatment of patients with COVID-19 and other respiratory complications caused by SARS-CoV-2 infection. The paper covers all kinds of human studies (January 2020 to June 2021) except case reports/series to highlight the clear conclusion based on the current clinical evidence. Among the promising repositioned antivirals, remdesivir has been recommended in critical conditions to mitigate the fatality rate and improve clinical conditions. In addition, boosting the immune system is believed to be beneficial in treating COVID-19 patients, so interferon type I might exert immunomodulation through its antiviral effects by stimulating interferon-stimulated gene (ISG). However, more extensive clinical studies covering all ethnic groups globally are warranted based on current data to better understand the clinical efficacy of the currently proposed repurposed drugs against COVID-19.

show abstract

Drug treatments for covid-19: living systematic review and network meta-analysis

Siemieniuk

Bartoszko

Zeraatkar

et al. 2020

BMJ

677

659

View full text Add to dashboard Cite

ObjectiveTo compare the effects of treatments for coronavirus disease 2019 (covid-19).DesignLiving systematic review and network meta-analysis.Data sourcesUS Centers for Disease Control and Prevention COVID-19 Research Articles Downloadable Database, which includes 25 electronic databases and six additional Chinese databases to 20 July 2020.Study selectionRandomised clinical trials in which people with suspected, probable, or confirmed covid-19 were randomised to drug treatment or to standard care or placebo. Pairs of reviewers independently screened potentially eligible articles.MethodsAfter duplicate data abstraction, a bayesian random effects network meta-analysis was conducted. Risk of bias of the included studies was assessed using a modification of the Cochrane risk of bias 2.0 tool, and the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. For each outcome, interventions were classified in groups from the most to the least beneficial or harmful following GRADE guidance.Results23 randomised controlled trials were included in the analysis performed on 26 June 2020. The certainty of the evidence for most comparisons was very low because of risk of bias (lack of blinding) and serious imprecision. Glucocorticoids were the only intervention with evidence for a reduction in death compared with standard care (risk difference 37 fewer per 1000 patients, 95% credible interval 63 fewer to 11 fewer, moderate certainty) and mechanical ventilation (31 fewer per 1000 patients, 47 fewer to 9 fewer, moderate certainty). These estimates are based on direct evidence; network estimates for glucocorticoids compared with standard care were less precise because of network heterogeneity. Three drugs might reduce symptom duration compared with standard care: hydroxychloroquine (mean difference −4.5 days, low certainty), remdesivir (−2.6 days, moderate certainty), and lopinavir-ritonavir (−1.2 days, low certainty). Hydroxychloroquine might increase the risk of adverse events compared with the other interventions, and remdesivir probably does not substantially increase the risk of adverse effects leading to drug discontinuation. No other interventions included enough patients to meaningfully interpret adverse effects leading to drug discontinuation.ConclusionGlucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care. The effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.Systematic review registrationThis review was not registered. The protocol is included as a supplement.Readers’ noteThis article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication.

show abstract

Efficacy and Safety of Arbidol in Treatment of Patients with COVID-19 Infection: A Randomized Clinical Trial

Cited by 3 publications

References 17 publications

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020

Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far

Drug treatments for covid-19: living systematic review and network meta-analysis

Contact Info

Product

Resources

About